VYGR - ボイジャ―・セラピュ―ティクス (Voyager Therapeutics Inc.) ボイジャ―・セラピュ―ティクス

 VYGRのチャート


 VYGRの企業情報

symbol VYGR
会社名 Voyager Therapeutics Inc (ボイジャ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ボイジャー・セラピューティクス(Voyager Therapeutics Inc.)は臨床段階の遺伝子治療会社である。同社は中枢神経系(CNS)疾患患者向け治療法の開発を行う。同社のパイプラインは進行性パーキンソン病、筋萎縮性側索硬化症(ALS)の単一遺伝子病、ハンチントン病、フリードライヒの運動失調、前頭側頭型認知症・アルツハイマー病及び慢性疼痛を含むCNS適応症向けプログラムを含む。同社の臨床的製品候補であるVY-AADC01は進行性パーキンソン病の治療向けアデノ随伴ウイルス(AAV)遺伝子治療薬候補である。VY-AADC01は複数のAAV遺伝子治療臨床試験に使用されるAAV2キャプシドと芳香族L-アミノ酸デカルボキシラーゼ(AADC)トランスジーンの発現を駆動するサイトメガロウイルスプロモーターを含む。パイプラインにはVY-SOD101、VY-FXN01、VY-HTT01、VY-TAU01、VY-NAV01を含む。   ボイジャ―・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、中枢神経系の疾患に対する遺伝子治療の開発に従事。特定のタンパク質に焦点を当て、アデノ随伴ウイルス遺伝子治療のアプロ―チにより症状の進行を遅らせることを目的とする。主にパ―キンソン病、脊髄筋萎縮症、ハンチントン舞踏病などの治療に貢献する。本社はマサチュ―セッツ州ケンブリッジ。   Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases.
本社所在地 75 Sidney Street Cambridge MA 02139 USA
代表者氏名 Mark J. Levin マーク・J.レヴィン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-259-5340
設立年月日 41426
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 89人
url www.voyagertherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vygr
adr_tso
EBITDA EBITDA(百万ドル) -80.64900
終値(lastsale) 16.96
時価総額(marketcap) 550114712.64
時価総額 時価総額(百万ドル) 509.24530
売上高 売上高(百万ドル) 11.01000
企業価値(EV) 企業価値(EV)(百万ドル) 313.12230
当期純利益 当期純利益(百万ドル) -80.64200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Voyager Therapeutics Inc revenues increased 33% to $3.5M. Net loss increased 28% to $45.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $1.8M to $7.9M (expense) General and administrative increase of 45% to $11M (expense).

 VYGRのテクニカル分析


 VYGRのニュース

   Analysts Predict A Surge In Voyager Therapeutics Inc. (NASDAQ: VYGR)?  2022/06/25 16:00:00 Stocks Register
Voyager Therapeutics Inc. (NASDAQ:VYGR) shares, rose in value on Friday, 06/24/22, with the stock price down by -1.37% to the previous day’s close as strong demand from buyers drove the stock to $5.76. Actively observing the price movement in the last trading, the stock closed the session at $5.84, falling within a range of $5.66 … Analysts Predict A Surge In Voyager Therapeutics Inc. (NASDAQ: VYGR)? Read More »
   Voyager Therapeutics Inc. (NASDAQ: VYGR) Has Advanced 11.36% In 2022; Is The Share Price Attractive Enough At $10.00?  2022/06/18 14:00:00 Marketing Sentinel
Voyager Therapeutics Inc. (NASDAQ:VYGR)’s traded shares stood at 0.17 million during the last session, with the company’s beta value hitting 1.12. At the close of trading, the stock’s price was $5.00, to imply an increase of 3.73% or $0.18 in intraday trading. The VYGR share’s 52-week high remains $10.60, putting it -112.0% down since that … Voyager Therapeutics Inc. (NASDAQ: VYGR) Has Advanced 11.36% In 2022; Is The Share Price Attractive Enough At $10.00? Read More »
   Voyager Therapeutics Inc. (NASDAQ:VYGR) Stock Boosted 99.26% So Far In 2022, What Analysts Expect Next?  2022/06/11 15:00:00 Marketing Sentinel
In last trading session, Voyager Therapeutics Inc. (NASDAQ:VYGR) saw 0.44 million shares changing hands with its beta currently measuring 1.10. Company’s recent per share price level of $5.40 trading at -$0.03 or -0.55% at ring of the bell on the day assigns it a market valuation of $197.05M. That closing price of VYGR’s stock is … Voyager Therapeutics Inc. (NASDAQ:VYGR) Stock Boosted 99.26% So Far In 2022, What Analysts Expect Next? Read More »
   Looking Back In On Voyager Therapeutics  2022/06/08 21:55:55 Seeking Alpha
Voyager Therapeutics has signed licensing deals with two large drug makers since we last looked in on it. Read what to know about VYGR stock here.
   Pharmaceutical Drug Development Sector Scorecard 2022: High-Value Deals Continue to Drive the Immuno-oncology and Genomics Markets But Several Companies Sell Biosimilar Portfolios - ResearchAndMarkets.com  2022/06/07 09:03:00 Kwhen Finance
   Looking Back In On Voyager Therapeutics  2022/06/08 21:55:55 Seeking Alpha
Voyager Therapeutics has signed licensing deals with two large drug makers since we last looked in on it. Read what to know about VYGR stock here.
   Pharmaceutical Drug Development Sector Scorecard 2022: High-Value Deals Continue to Drive the Immuno-oncology and Genomics Markets But Several Companies Sell Biosimilar Portfolios - ResearchAndMarkets.com  2022/06/07 09:03:00 Kwhen Finance
   Voyager Therapeutics'' TRACER Capsids Show Encouraging Action In Animal Models  2022/05/19 12:38:06 Benzinga
Voyager Therapeutics Inc (NASDAQ: VYGR ) will present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction at the American Society of Gene and Cell Therapy Annual Meeting. Voyager''s TRACER capsid discovery platform has identified a novel AAV9-derived capsid, VCAP-102, which demonstrated 50-fold better transduction in mice and … Full story available on Benzinga.com
   Voyager Therapeutics'' TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs  2022/05/19 10:00:00 Benzinga
VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target CNS disorders, including certain diseases that may benefit from glial cell targeting Preclinical data demonstrate potential to ameliorate disease in models of GBA1, tauopathies, and SOD1 ALS Results presented at the American Society of Gene and Cell Therapy 25th Annual Meeting CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today is scheduled to present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system (CNS) transduction. The Company is also scheduled to report updated results from preclinical gene therapy programs in GBA1, tauopathies, and SOD1 ALS.
   Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting  2022/05/16 10:00:00 Wallstreet:Online
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid improved transduction in multiple CNS regions and cell types in non-human primates with partial detargeting of the dorsal root ganglia CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics,
   Voyager Therapeutics plunges after update on board composition  2022/04/21 19:55:23 Seeking Alpha
The shares of gene therapy company, Voyager Therapeutics (VYGR) have recorded the biggest intraday loss on Thursday after announcing that two of its board members had requested not to…
   Biogen''s former top scientist takes CEO spot at Voyager Therapeutics  2022/03/22 14:52:58 Business Journals
Months after exiting the embattled Biogen Inc., Al Sandrock has stepped into the chief executive role at gene therapy firm Voyager Therapeutics Inc.
   STAT+: Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics  2022/03/22 12:25:53 STAT News
Al Sandrock, the top scientist at Biogen who exited last year in a dispute over its controversial Alzheimer’s treatment, has landed a new job as the CEO of Voyager Therapeutics,…
   Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics  2022/03/22 12:25:53 STAT News
His appointment is the latest in a series of moves aimed at refocusing the company on a new gene therapy delivery technology.
   Dr. Alfred W. Sandrock is the new CEO at Voyager therapeutics  2022/03/22 11:39:28 Seeking Alpha
Voyager Therapeutics (VYGR) appoints Alfred W. Sandrock, Jr., M.D., Ph.D

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ボイジャ―・セラピュ―ティクス VYGR Voyager Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)